Cargando…
IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis
IL-33 is a pleiotropic cytokine that promotes inflammation and fibrosis. IL-33 is produced by a broad range of cells, including antigen-presenting cells (APCs), epithelial cells, and fibroblasts. IL-33 produced by the innate immune cells has been shown to activate pro-inflammatory T helper type 1 (T...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573230/ https://www.ncbi.nlm.nih.gov/pubmed/34759844 http://dx.doi.org/10.3389/fphys.2021.781012 |
_version_ | 1784595377785143296 |
---|---|
author | Kurimoto, Masayuki Watanabe, Tomohiro Kamata, Ken Minaga, Kosuke Kudo, Masatoshi |
author_facet | Kurimoto, Masayuki Watanabe, Tomohiro Kamata, Ken Minaga, Kosuke Kudo, Masatoshi |
author_sort | Kurimoto, Masayuki |
collection | PubMed |
description | IL-33 is a pleiotropic cytokine that promotes inflammation and fibrosis. IL-33 is produced by a broad range of cells, including antigen-presenting cells (APCs), epithelial cells, and fibroblasts. IL-33 produced by the innate immune cells has been shown to activate pro-inflammatory T helper type 1 (Th1) and T helper type 2 (Th2) responses. The intestinal barrier and tolerogenic immune responses against commensal microbiota contribute to the maintenance of gut immune homeostasis. Breakdown of tolerogenic responses against commensal microbiota as a result of intestinal barrier dysfunction underlies the immunopathogenesis of inflammatory bowel diseases (IBD) and pancreatitis. Recent studies have provided evidence that IL-33 is an innate immune cytokine that bridges adaptive Th1 and Th2 responses associated with IBD and pancreatitis. In this Mini Review, we discuss the pathogenic roles played by IL-33 in the development of IBD and pancreatitis and consider the potential of this cytokine to be a new therapeutic target. |
format | Online Article Text |
id | pubmed-8573230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85732302021-11-09 IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis Kurimoto, Masayuki Watanabe, Tomohiro Kamata, Ken Minaga, Kosuke Kudo, Masatoshi Front Physiol Physiology IL-33 is a pleiotropic cytokine that promotes inflammation and fibrosis. IL-33 is produced by a broad range of cells, including antigen-presenting cells (APCs), epithelial cells, and fibroblasts. IL-33 produced by the innate immune cells has been shown to activate pro-inflammatory T helper type 1 (Th1) and T helper type 2 (Th2) responses. The intestinal barrier and tolerogenic immune responses against commensal microbiota contribute to the maintenance of gut immune homeostasis. Breakdown of tolerogenic responses against commensal microbiota as a result of intestinal barrier dysfunction underlies the immunopathogenesis of inflammatory bowel diseases (IBD) and pancreatitis. Recent studies have provided evidence that IL-33 is an innate immune cytokine that bridges adaptive Th1 and Th2 responses associated with IBD and pancreatitis. In this Mini Review, we discuss the pathogenic roles played by IL-33 in the development of IBD and pancreatitis and consider the potential of this cytokine to be a new therapeutic target. Frontiers Media S.A. 2021-10-25 /pmc/articles/PMC8573230/ /pubmed/34759844 http://dx.doi.org/10.3389/fphys.2021.781012 Text en Copyright © 2021 Kurimoto, Watanabe, Kamata, Minaga and Kudo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Kurimoto, Masayuki Watanabe, Tomohiro Kamata, Ken Minaga, Kosuke Kudo, Masatoshi IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis |
title | IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis |
title_full | IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis |
title_fullStr | IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis |
title_full_unstemmed | IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis |
title_short | IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis |
title_sort | il-33 as a critical cytokine for inflammation and fibrosis in inflammatory bowel diseases and pancreatitis |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573230/ https://www.ncbi.nlm.nih.gov/pubmed/34759844 http://dx.doi.org/10.3389/fphys.2021.781012 |
work_keys_str_mv | AT kurimotomasayuki il33asacriticalcytokineforinflammationandfibrosisininflammatoryboweldiseasesandpancreatitis AT watanabetomohiro il33asacriticalcytokineforinflammationandfibrosisininflammatoryboweldiseasesandpancreatitis AT kamataken il33asacriticalcytokineforinflammationandfibrosisininflammatoryboweldiseasesandpancreatitis AT minagakosuke il33asacriticalcytokineforinflammationandfibrosisininflammatoryboweldiseasesandpancreatitis AT kudomasatoshi il33asacriticalcytokineforinflammationandfibrosisininflammatoryboweldiseasesandpancreatitis |